Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2011	Dec. 31, 2010
Assets
Cash and cash equivalents	$ 212,280	$ 478,668
Grant receivable	0	244,479
Debt issue costs	0	4,408
Other current assets	100,759	141,622
Total current assets	313,039	869,177
In-process research and development	17,742,110	17,742,110
Property and equipment, net	1,580	2,984
Other assets	7,750	21,370
Total assets	18,064,479	18,635,641
Liabilities and Stockholders' Deficiency
Notes payable, current portion, net of discount	761,314	2,054,246
Accounts payable and accrued expenses	167,719	223,516
Interest payable, current portion, net of beneficial conversion	47,223	480,890
Derivative liability	538,830	534,846
Total current liabilities	1,515,086	3,293,498
Notes payable, noncurrent portion, net of discount	16,388,797	16,130,571
Interest payable, noncurrent portion	455,214	626,697
Exchange obligation	0	3,949,176
Total liabilities	18,359,097	23,999,942
Commitments and contingencies
Stockholders' deficiency:
Preferred stock, $.001 par value. Authorized 1,500,000 shares; no shares issued and outstanding at September 30, 2011 and December 31, 2010	0	0
Common stock, value issued	7,398	2,419
Additional paid-in capital	60,693,779	55,927,180
Deficit accumulated during the development stage	(61,011,685)	(61,309,790)
Total stockholders' deficiency	(294,618)	(5,364,301)
Total liabilities and stockholders' deficiency	18,064,479	18,635,641
Contingently Issuable Share [Member]
Stockholders' deficiency:
Common stock, value issued	$ 15,890	$ 15,890